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This study investigated the role of the complement activation fragmentC5a in secondarypathology following contusive spinal cord injury
(SCI).C5ar/mice, which lack the signaling receptor for C5a, displayed signs of improved locomotor recovery and reduced inflamma-
tion during the first week of SCI compared with wild-type mice. Intriguingly, the early signs of improved recovery in C5ar/ mice
deteriorated fromday 14 onward,with absence of C5aRultimately leading to poorer functional outcomes, larger lesion volumes, reduced
myelin content, andmore widespread inflammation at 35 d SCI. Pharmacological blockade of C5aRwith a selective antagonist (C5aR-A)
during the first 7 d after SCI improved recovery compared with vehicle-treated mice, and this phenotype was sustained up to 35 d after
injury. Consistent with observations made in C5ar/ mice, these improvements were, however, lost if C5aR-A administration was
continued into themore chronic phase of SCI. Signaling through the C5a-C5aR axis thus appears injurious in the acute period but serves
a protective and/or reparative role in the post-acute phase of SCI. Further experiments in bonemarrow chimericmice suggested that the
dual and opposing roles of C5aR on SCI outcomes primarily relate to its expression on CNS-resident cells and not infiltrating leukocytes.
Additional in vivo and in vitro studies provided direct evidence that C5aR signaling is required during the postacute phase for astrocyte
hyperplasia, hypertrophy, and glial scar formation. Collectively, these findings highlight the complexity of the inflammatory response to
SCI and emphasize the importance of optimizing the timing of therapeutic interventions.
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Introduction
The complex inflammatory response to traumatic spinal cord
injury (SCI) contains elements that are known to be required for
successful wound healing in other tissues; in context of CNS in-
jury, these can, however, also cause additional damage to spared
neural tissue (Donnelly and Popovich, 2008). A more in-depth
understanding of these seemingly opposing roles of inflamma-
tion is therefore required, such that new and effective
immune-modulatory therapies can be developed to improve
recovery from SCI, and potentially other acquired CNS inju-
ries. The innate immune complement system, composed of
30 soluble and membrane-bound proteins, receptors, and
regulators, is a major component of trauma-induced neuro-
inflammation (Anderson et al., 2004; Brennan et al., 2012).
Previous studies have already shown that SCI outcomes can be
improved through genetic deletion or pharmacological block-
ade of complement opsonins (Ankeny et al., 2009), the lytic
membrane attack complex (Li et al., 2009), as well as more
general interference with the main (i.e., classical, lectin, and
alternative) pathways for complement system activation
(Reynolds et al., 2004; Qiao et al., 2006, 2010; Guo et al., 2010).
The role of the C5a activation fragment in the immune re-
sponse to SCI remains, however, uncertain.
C5a is a 74 amino acid peptide that is generated by the
proteolysis of complement protein C5. It is known to be a
potent chemoattractant molecule through interaction with its
G-protein-coupled receptor C5aR (CD88) (Ward and Newman,
1969), which is present on most leukocytes (Chenoweth and
Hugli, 1978; Chenoweth et al., 1982). In the CNS, C5aR expres-
sion has been reported on neurons (Stahel et al., 1997; O’Barr et
al., 2001; Be´nard et al., 2004; Woodruff et al., 2006; Humayun et
al., 2009), astrocytes (Gasque et al., 1995; Lacy et al., 1995;Wood-
ruff et al., 2008), microglia (Lacy et al., 1995; Griffin et al., 2007),
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oligodendrocytes (Nataf et al., 2001), and neural progenitor cells
(Farkas et al., 1999; Rahpeymai et al., 2006).
Previous in vivo studies have shown that parenchymal C5a/
C5aR expression is increased in models of traumatic brain injury
(Stahel et al., 1997), intracerebral hemorrhage (Xi et al., 2001),
and ischemic injury (Van Beek et al., 2000; Pavlovski et al., 2012),
as well as in the plasma of human patients with stroke (Mocco et
al., 2006) and subarachnoid hemorrhage (Mack et al., 2007).
More importantly, acute inhibition of the C5a-C5aR axis im-
proves outcomes from experimental ischemic stroke (Kim et al.,
2008; Pavlovski et al., 2012) and intracerebral hemorrhage (Gar-
rett et al., 2009). Intriguingly, although acute C5aR blockade is
thought to attenuate inflammation, delayed antagonism of this
receptor, starting 2 weeks after injury, led to significantly exacer-
bated SCI outcomes (Beck et al., 2010). These findings suggest a
novel neuroprotective/reparative role for C5aR signaling in the
postacute phase of neurotrauma, although the mechanisms be-
hind these observations are poorly understood. In the present
study, we used C5aR knock-out (C5ar/) mice, pharmacolog-
ical targeting of C5aR, bone marrow chimeras, and in vitro stud-
ies to better understand the role of the C5a-C5aR axis in SCI.
Materials andMethods
Animals. Adult female age- and weight-matched C57BL/6J (wild-type
[WT]; n  147), C5ar/ (n  62) (Hollmann et al., 2008), and
Macgreen (Csf1r-EGFP, n 24) (Sasmono et al., 2003)micewere used in
this study. C5ar/ and Macgreen mice had been backcrossed for10
generations onto the C57BL/6J genetic background. All animals were
obtained from local breeding colonies at the University of Queensland’s
Biological Resources facility. Mice were maintained in individually ven-
tilated cages under standard conditions on a 12 h light-dark cycle with ad
libitum access to food and water. All experimental procedures were ap-
proved by the University of Queensland’s Animal Ethics Committee and
conducted in accordance with the relevant National Health andMedical
Research Council of Australia policies.
SCI. Mice were anesthetized with a mixture of tiletamine/zolezepam
(50 mg/kg; Virbac) and xylazine (20 mg/kg; Troy Laboratories), after
which they underwent contusive SCI. In brief, this involved identifica-
tion of the ninth thoracic (T) vertebra based on anatomical landmarks
(Harrison et al., 2013), followed by dorsal laminectomy of T9 as de-
scribed previously (Scheff et al., 2003; Blomster et al., 2013a). Next, a
severe (70 kdyne) contusion injury was inflicted on the spinal cord
using the Infinite Horizon impactor device (Precision Systems and In-
strumentation). Following this, muscle and skin were closed separately
using 6–0 polyglactin dissolvable sutures (Ethicon) and Michel wound
clips (Kent Scientific), respectively. Investigators performing surgery
were blinded to the genotype and/or treatment condition of the animals.
Postoperatively, animals received a single injection of buprenorphine
(0.5 mg/kg s.c.) in Hartmann’s sodium lactate solution for analgesia and
were administered antibiotics (1.0mg/kg gentamicin s.c.) for the first 5 d
after injury. Bladders were manually voided twice daily for the duration
of the experiments.
C5a ELISA. To determine the time course of C5a generation following
SCI, WT mice were subjected to either SCI or sham surgery and then
killed with sodium pentobarbitone (100 mg/kg i.p., Virbac) at 30 min,
2 h, 6 h, 12 h, 1 d, 4 d, 7 d, or 35 d after injury (n 4 or 5 per time point).
An additional 4 unoperated (i.e., naive) mice were used to assess C5a
levels under normal homeostatic conditions (time point 0).
At the appropriate time point, 0.5 ml of volume of blood was collected
directly from the heart via cardiac puncture using a syringe containing 30
l of 4 mM EDTA. Blood samples were mixed immediately with 10 l of
the complement inhibitor FUT175 (5mg/ml; BDBiosciences) and stored
on ice. Samples were centrifuged at 13,000  g for 10 min at 4°C, after
which the supernatant was collected, aliquoted, and stored at 80°C.
The T11-T13 spinal cord segment was also dissected immediately after
the cardiac bleed, snap frozen in liquid nitrogen, and then stored at
80°C. Spinal cord samples were ground to a fine powder using amortar
and pestle on dry ice, then dissolved in 200 l of NP-40 lysis buffer
(Invitrogen) containing 1 mM PMSF (reconstituted in DMSO) (Sigma-
Aldrich), 92.6 M FUT175 (BD Biosciences), and 5 l of protease inhib-
itor mixture (Sigma-Aldrich). Samples were vortexed for 1 min,
incubated on ice for 1 h, and then centrifuged at 13,000 g for 30min at
4°C. Supernatants were collected, aliquoted, and stored at 80°C. An
ELISA (R&D Systems, #DY2150) was then used to determine the con-
centration of C5a in blood plasma and spinal cord samples according to
the manufacturer’s instructions; all samples were detected within the
linear aspect of the standard curve. For spinal cord samples, the mea-
sured concentration of C5a was always normalized to the protein con-
centration of the sample, which was measured by a BCA protein assay
(Thermo Scientific, #23227) according to the manufacturer’s
instructions.
Tissue processing for MRI and histology. Mice were anesthetized with
sodium pentobarbitone (100 mg/kg i.p., Virbac) at their specified end-
points (see Results).Mice were then transcardially perfusedwith 20ml of
saline (0.9% NaCl) containing 10 IU/ml heparin (Pfizer) and 2%
NaNO3, followed by 30 ml of phosphate-buffered Zamboni’s fixative
(2% picric acid, 2% formaldehyde, pH 7.2–7.4). The perfused vertebral
column was then dissected out and postfixed overnight at 4°C. Spinal
cord specimens were then imaged where applicable (see MRI), dissected
out from the vertebral column, and cryoprotected via subsequent over-
night incubations in 10% and 30% sucrose solutions. Next, the lesion
segment of the spinal cord was embedded in Optimal Cooling Temper-
ature (OCT) compound (ProSciTech), snap-frozen using dry ice-cooled
isopentane, and then stored at80°C until sectioning. Coronal sections
(20 m thick) were cut on a Leica cryostat CM3050-S, collected on
Superfrost Plus slides (1:5 series; Lomb Scientific), and stored at80°C
until staining.
Analysis of C5aR expression. Immunofluorescent staining techniques
were used to assess the expression and distribution of C5aR in the injured
spinal cord. A rat anti-C5aR antibody (clone 10/92, 1:200; AbD Serotec)
was used for these experiments. Antibody specificity was confirmed
through staining of spinal cord tissue from injuredC5ar/mice, aswell
as omission of the primary antibody incubation step onWT tissue. Stain-
ing for C5aR was combined with immunolabeling for ionized calcium
binding adaptor molecule 1 (rabbit anti-Iba1, 1:500; Wako Pure Chem-
ical Industries) to label microglia/macrophages, or with GFAP (rabbit
anti-GFAP, 1:1000;Dako) to identify astrocytes. Slideswere defrosted for
1 h at room temperature (RT) and then washed in PBS (3  10 min).
Next, slides were incubated in blocking solution (0.2% Triton X-100,
Sigma-Aldrich; 2% BSA, Sigma-Aldrich; in PBS) for 1 h at RT to perme-
abilize the sections and reduce nonspecific antibody binding. This solu-
tion was also used as the antibody diluent. After blocking, spinal cord
sections were incubated overnight at 4°C with primary antibodies in a
humidified chamber. The following day, slides were washed in PBS (3
10 min) to remove unbound antibody, followed by incubation with sec-
ondary antibodies goat anti-rat IgG-AlexaFluor-555 (1:500; Invitrogen)
and goat anti-rabbit IgG-AlexaFluor-488 (1:200; Invitrogen) for 1 h at
RT. Slides were then washed again in PBS (3  10 min), coverslipped
with Dako fluorescent mounting medium containing Hoechst 33342
nuclear dye (1:1000; Sigma-Aldrich), and imaged using an Olympus
BX61 confocal microscope.
Assessment of functional recovery.Mouse hindlimb locomotor recovery
in WT and C5ar/mice was assessed at 1, 3, 7, 10, 14, 21, 28, and 35 d
after injury using the 10 point Basso Mouse Scale (BMS), which is spe-
cifically designed for mouse models of SCI (Basso et al., 2006). Two
investigators assessed various aspects of each mouse’s locomotion in
open field for 4 min. For mice that achieved a score of frequent plantar
stepping (i.e., a BMS score  5), BMS subscores were also assigned to
quantify the finer aspects of locomotion. For the initial experiments
comparing the recovery of WT and conventional C5ar/ mice, the
actual applied force was 71.9 0.56 kdyne (n 12, mean SEM) and
72.2 0.52 kdyne (n 8,mean SEM), with an average tissue displace-
ment of 593.4 6.57m (mean SEM) and 597.4 9.71m (mean
SEM), respectively. There were no significant differences in injury pa-
rameters between experimental groups (p 0.05).
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For pharmacological studies involving C5aR antagonism during the
first week of injury (see C5aR-A treatment), ledged tapered beam walk-
ing was used as a second, independent measure to assess hindlimb loco-
motor ability. The beam itself, which was elevated 1 m above the floor,
was 90 cm long and had a starting width of 3 cm that narrowed to 0.5 cm
at the end. Mice were trained to cross the beam for 5 consecutive times
during 2 d of habituation trials before the testing day. On the test day
itself (35 d after SCI), eachmouse was again required to cross the beam 5
times and videotaped while performing the task. The total number of
steps, the number of footfalls, and the traversing time were recorded. For
each animal, the mean data from the five crossings were calculated for
each of these parameters. A group of sham-operated Macgreen mice
(n  6) was included to determine baseline performance for this
functional task. Assessors were blinded to the experimental condition
(genotype/treatment group) during all behavioral testing to avoid
experimenter bias.
MRI. For postmortem MRI analysis at 35 d after injury, spinal cord
samples were washed extensively in 0.1MPBS after overnight postfixing,
followed by immersion for 48 h in PBS containing gadolinium contrast
agent (0.2% Magnevist, Bayer HealthCare Pharmaceuticals). Vertebral
columnswith the spinal cord in situwere imaged on a 16.4T small animal
MRI (Bruker BioSpin) as detailed previously (Blomster et al., 2013b). A
stack of 256 two dimensional T2 slices was generated for each imaged
specimen.MRI datasets were analyzed using AVIZO version 6.2 software
(Visualization Sciences Group), with an orthoslice along the sagittal
plane and two user-defined (oblique) slices along the coronal and trans-
verse planes, respectively. The Apply-Transform function was used to set
these axes as the reference points for further analyses. A 3D image of the
lesion core was reconstructed by manually outlining the hypointense
core in the coronal plane of every slice using the Lasso tool; the sagittal
and transverse planes were also viewed to confirm that the complete
lesion core was highlighted. As areas of demyelination can be difficult to
distinguish from remnants of spared gray matter, only the hypointense
core was outlined for reconstruction and calculation of lesion volumes.
Image quantification was performed with the investigator blinded to the
experimental group.
General staining procedures and analysis of histopathology. Fluoro-
Myelin Red staining (1:150; Invitrogen) was performed as per the man-
ufacturer’s instructions to assess white matter myelin content at and
around the lesion site (Blomster et al., 2013a). FluoroMyelinRed staining
was combined with immunostaining for GFAP as detailed above, except
for experiments that involved Macgreen mice, where a separate set of
sections were stained for GFAP using a goat anti-rabbit IgG-AlexaFluor-
546 secondary antibody (1:250; Invitrogen). Stained spinal cord sections
were photographed using an Olympus SZX12 Research Fluorescence
Stereo Microscope (Spectra Services). The proportional area of myelin
and GFAP staining (relative to the section area) was measured using the
freehand selection tool and threshold functions in ImageJ. The average
pixel intensity for GFAP immunofluorescence was also determined as
detailed previously (Schmid et al., 2013). For each experimental animal,
the lesion epicenter was defined as the coronal section with the least
amount of FluoroMyelin Red staining relative to the section area (Blom-
ster et al., 2013a). Image acquisition and data analysis were again per-
formed with experimenter blinding.
To evaluate the cellular immune response in the injured spinal cord,
immunohistochemical staining with rat anti-Ly6b.2 (1:400; AbD Sero-
tec) was used to visualize infiltrating neutrophils (and a subset of inflam-
matory monocytes) (Rosas et al., 2010). Rat anti-CD11b (1:200; AbD
Serotec) was used to label granulocytes, macrophages, andmicroglia. Rat
anti-CD3 (1:400; AbD Serotec) was used to stain T lymphocytes. For all
of these stains, slides were first washed in PBS (3 10 min). To quench
endogenous peroxidase activity, slides were incubated at RT in PBS con-
taining 10%methanol for 10min and then incubated for 20min at RT in
PBS containing 10%methanol and 0.3%H2O2. Slides were then washed
again in PBS (3 10 min) and incubated with blocking solution for 1 h
at RT, before overnight incubation with primary antibody in a humidi-
fied chamber at 4°C. The following day, slides were washed in PBS and
incubated for 1.5 h at RT with biotinylated donkey anti-rat IgG (1:250;
AbD Serotec). Sections were then washed again in PBS (3 10min) and
incubated with Vectastain Elite ABC reagent (1:200; Vector Laborato-
ries) for 1 h at RT. After another set of 3  10 min washes in PBS, the
staining was developed by incubating each slide for 5 min at RT with 0.5
ml of 3,3-diaminobenzidine (Sigma-Aldrich). Stained sections were de-
hydrated through graded series of ethanol (70%–100%), washed twice in
xylene, and coverslipped using Depex mounting media (Electron Mi-
croscopy Sciences). Immunohistochemically stained slides were digi-
tized using a ScanScope XT scanner (Aperio) and ImageScope (Leica
Biosystems).
For quantitative analysis, Ly6b.2 and CD3 cell numbers in the
spinal cordwere counted using themanual tag function in ImageProPlus
Version 6.3 (Media Cybernetics) and expressed as number of cells per
mm2 based on the section area outlined in ImageJ. The CD11b im-
mune infiltratewas quantified and expressed as a proportional area of the
section (Kigerl et al., 2006). The analyzer was blinded to the experimental
condition during counting and image analysis.
C5aR-A treatment. A cohort of Macgreen mice was used for pharma-
cological inhibition of C5aR during the acute/subacute phase. These
mice underwent SCI as described above and then administered either
the cyclic C5aR peptide antagonist (C5aR-A; [hydrocinnamate-
(OPdChaWR)], 1 mg/kg, i.p., n  8) (Finch et al., 1999) or a vehicle
solution (5% glucose, i.p., n  10). Treatment started at 30 min after
injury and was repeated every 12 h for the first 7 d after injury. The actual
applied force for this experiment was 72.5 0.65 kdyne and 72.5 0.54
kdyne (mean SEM) for vehicle-treated and C5aR-A-treated mice, re-
spectively. The associated tissue displacement was 539.2  7.5 m and
528.7 12.4m(mean SEM), respectively. There were no differences
in injury parameters between groups (p  0.05). These mice were sub-
jected to BMS scoring, ledged tapered beam walking, and postmortem
analysis of histopathology, all as detailed earlier.
In a separate experiment, WT mice were subjected to SCI and treated
with either C5aR-A (n  4) or vehicle (n  5) as detailed above, every
12 h until the experimental endpoint of 21 d after SCI. The actual applied
force here was 72.0 1 kdyne (mean SEM) for C5aR-A-treated mice
and 72.60 0.68 kdyne (mean SEM) for vehicle-treated controls; the
associated tissue displacement was 534.7  25.9 m and 522.7  29.7
m (mean SEM), respectively. A cohort ofC5ar/mice (n 5) was
also included in this experiment; the applied force for these animals was
72.8 0.8 kdyne (mean SEM), with an associated tissue displacement
of 521.6 33.4 m (mean SEM). There were no differences in injury
severity parameters between experimental groups (p 0.05). All of the
animals in this experiment were also injected with the thymidine analog
BrdU (BDBiosciences, 50mg/kg, i.p.) every 24 h for the first 7 d after SCI
to label proliferating cells (see below). This period was chosen for BrdU
injection as it is thought to capture the onset of oligodendrocyte precur-
sor cell and astrocyte proliferation after rodent CNS trauma (Bush et al.,
1999; Zai and Wrathall, 2005; Lytle and Wrathall, 2007; Tripathi and
McTigue, 2007; Wanner et al., 2013). Functional recovery in this exper-
iment was monitored via BMS scoring with investigator blinding.
Cytokine quantification. For analysis of cytokine levels in acute SCI, the
injured spinal cord segment (vertebral levels T8-T10) from bothWT and
C5ar/ mice was collected at 12 h after SCI (n  5 per group) and
processed as detailed earlier (see C5a ELISA). This segment of spinal cord
was also collected from sham-operated (i.e., laminectomy with no sub-
sequent SCI)WT andC5ar/mice to establish baseline cytokine levels
(n 4 per group).
The concentrations of CXCL1 and IL-1 in spinal cord supernatants
were determined using cytokine Flex Sets (BD Biosciences, #558340 and
#560232, respectively). Levels of IL-12p70, TNF, IFN, MCP-1, IL-10,
and IL-6 were also determined using a Cytometric Bead Array (BD Bio-
sciences, #552364) as per the manufacturer’s instructions. The latter
sampleswere analyzed on an LSRII flow cytometer (BDBiosciences), and
concentrations computed using FCAP array version 3.0 software. For all
assays, samples were appropriately diluted, such that they were always
detected within the linear aspect of the standard curves. The calculated
cytokine concentrations were normalized to the total protein content of
each sample, which was measured by a BCA protein assay (Thermo Sci-
entific, #23227) according to the manufacturer’s instructions.
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Flow cytometry. Flow cytometrywas used to quantify the inflammatory
infiltrate in the injured spinal cord at 7 d after SCI. In brief, injured spinal
cord of WT and C5ar/ mice (T11–13 segments) was dissociated as
reported previously (Beck et al., 2010; Blomster et al., 2013a). Cells were
then resuspended in flow cytometry blocking buffer (0.5% BSA, 2 mM
EDTA, in DPBS, pH 7.2), followed by incubation with rat-anti-CD16/32
(1:200; BD Biosciences) for 10 min at 4°C to block Fc receptors. Cells
were immunolabeled with rat anti-Ly6G-Alexa-647 (1:200, BD Biosci-
ences), rat anti-Ly6C-V450 (1:200; BD Biosciences), and rat anti-
CD45-PE (1:200; BD Biosciences). For the exclusion of dead cells,
samples were also incubated with near infrared-conjugated viability dye
(Zombie NIR, 1:100; BioLegend). Stained samples were then analyzed
using an LSR II flow cytometer (BD Biosciences) and BD FACS Diva
software. After acquisition, compensation was applied to remove Zom-
bie NIR/Ly6G-Alexa-647 spectral overlap; cell doublets, triplets, etc.
were excluded based on FSC-A/FSC-H linearity. Inflammatory mono-
cytes/macrophages were defined as the CD45hiLy6CLy6G popula-
tion, and neutrophils as the CD45Ly6CLy6G population.
Propidium iodide-fluorescing counting beads (5 l; Beckman Coulter)
were added as an internal control to enable quantification of absolute cell
numbers according to the manufacturer’s instructions.
Bone marrow (BM) chimeras. To assess the impact of selective C5aR
deletion within the peripheral immune compartment on recovery from
SCI, [WT¡WT] (n 6), and [C5ar/¡WT] (n 7) BM chimeric
mice were generated as detailed previously (Chinnery et al., 2010). These
micewere allowed to recover for 8weeks after chimerization before being
subjected to SCI surgery as detailed above. For this experiment, the actual
applied forcewas 72.86 0.80 kdyne versus 72.29 0.87 kdyne (mean
SEM), with an associated tissue displacement of 518.6  14.9 m and
511.1  12.18 m (mean  SEM) for [WT¡ WT] and [C5ar/¡
WT] BM chimeras, respectively. There were no significant differences in
injury parameters between experimental groups (p  0.05). SCI out-
comes for these mice were assessed via BMS scoring and postmortem
analysis of histopathology as detailed earlier.
Assessment of glial cell proliferation and apoptosis. Spinal cord tissue
frommice that were chronically treated with C5aR-A, and also adminis-
tered BrdU during the first week following SCI, was used to determine
whether C5aR targeting influenced the proliferative response(s) of oligo-
dendrocyte precursor cells and astrocytes (study endpoint: 21 d after
SCI). Immunofluorescent staining of spinal tissuewas done using similar
procedures as described above, but with the inclusion of a denaturing
step (20 min incubation in 2 NHCl at 37°C) to expose the BrdU epitope
within the nuclear DNA. After blocking, sections were probed with rat
anti-BrdU antibody (1:100; AbD Serotec) in combination with rabbit
anti-GFAP (1:1000; Dako) for astrocytes, or mouse anti-CC1 (1:100;
Abcam) for oligodendrocytes. For the latter, the HistoMouse kit (Invit-
rogen) was used as per the manufacturer’s instructions to allow for the
use of mouse primary antibodies on mouse tissue. An incubation with
biotinylated donkey anti-rat IgG (1:200; Vector Laboratories) secondary
antibody (1 h at RT) was followed by a 1 h incubation with streptavidin-
AlexaFluor-546 (1:200; BDBiosciences), combinedwith either goat anti-
rabbit IgG-AlexaFluor-488 (1:200; Invitrogen) forGFAP staining orwith
goat anti-mouse IgG-AlexaFluor-488 (1:200; Invitrogen) for CC1 stain-
ing. Tiled optical sections were captured on a Zeiss fluorescence micro-
scopewithApoTome attachment, afterwhich the total BrdUGFAPor
BrdUCC1 cell numbers were counted in spinal cord cross-sections at
regular intervals away from the lesion epicenter, with the analyzer being
blinded to the experimental condition. Section areas were measured in
ImageJ (up to 1mmin rostral and caudal directions), allowing the cell count
tobe expressedasnumberof cells permm2.Lesionvolumes in these animals
were estimated by outlining the lesion core area (delineated by GFAP stain-
ing) in every relevant section using ImageJ; obtained values were thenmul-
tiplied by the section thickness and totaled for each animal.
To also compare and contrast oligodendrocyte cell death between the
various genotypes and/or experimental conditions at the study endpoint,
a separate set of sections were stained for CC1 and active Caspase-3
(anti-Cleaved Caspase-3 rabbit polyclonal; 1:200; BD Biosciences
PharMingen). The number of CC1CleavedCaspase-3 cells were then
counted within each section and expressed as the number of cells per
mm2 based on the section area outlined in ImageJ. The analyzer was
again blinded to the experimental condition during analysis.
In vitro astrocyte proliferation. Astrocyte cultures were established
from the brains of WT or C5ar/ pups (P1-P3; n  8 per culture)
(Gordon et al., 2011). In brief, brains were harvested, the meninges re-
moved, and the tissue placed in ice-cold DMEM/F-12 nutrient mixture
(Invitrogen, #11320) supplemented with 10% heat-inactivated FBS, 50
U/ml penicillin, 50g/ml streptomycin, 2mM L-glutamine, 100M non-
essential amino acids, and 2 mM sodium pyruvate (Invitrogen). The tis-
sue was then incubated in 0.25% trypsin (Sigma-Aldrich) at 37°C for 30
minwith gentle agitation. Trypsinizationwas stopped by adding an equal
volume of DMEM/F12 complete media, followed by three washes in the
samemedia. A single-cell suspension of the tissue was prepared by gentle
trituration and passing of the solution through a 70 m nylon mesh cell
strainer to remove tissue debris and aggregates, after which the remain-
ing cell suspension was seeded into two T-75 flasks per mouse brain.
Primary astrocytes were purified by daily media changes for 3 d and
residual microglial cells were maximally depleted by treatment with the
lysosomotropic agent leucinemethylester (5mM) for 6 h to obtain98%
pure astrocytes. The purity of astrocyte cultures was routinely verified by
immunocytochemistry for GFAP and Iba1.
For the proliferation assay, purified astrocytes were plated out at a
density of either 0.5 or 1 104 cells per well in a 48 well plate withmedia
containing DMEM/F12, 10% FBS, 1% nonessential amino acids, 1%
penicillin/streptomycin, 1% L-glutamine, and 1% sodium pyruvate. The
next day, cells were switched to media containing 2% FBS, and recombi-
nant mouse C5a (Hycult Biotech) was added at a concentration of 0, 5,
10, 50, 100, or 200 nM in triplicate. For experiments that aimed to deter-
mine whether phosphorylation of Signal Transducer and Activator of
Transcription 3 (STAT3) was involved in astrocyte proliferation in the
presence of C5a, 5 M of the STAT3 inhibitor (BP-1-102, Millipore) was
added 10 min before C5a (50 nM) exposure; BP-1-102 disrupts STAT3-
STAT3 dimerization and STAT3-phospho-tyrosine (pTyr) peptide in-
teractions (Zhang et al., 2012). Plates were then incubated for 48 h under
standard cell culture conditions (37°C, 5%CO2). The extent of astrocyte
proliferation under the various experimental conditions was measured
using a CyQUANT assay (Invitrogen) according to the manufacturer’s
instructions.
Western blotting. Separate sets of astrocyte cultures were established
and randomly allocated to one of the following groups: (1) no treatment,
(2) 50 nMC5a only, (3) 50 nMC5a 10MBP-1-102 (STAT3-inhibitor),
and (4) 10 M BP-1-102 only. Astrocytes were exposed to C5a for 1 h;
where applicable, BP-1-102 was added to the culture medium 10 min
before C5a exposure. After incubation, cells were scraped off the flasks
and collected via (low-speed) centrifugation at 300 g for 6min. Super-
natants were removed and the cell pellets stored at 80°C until lysis in
150l ofmodifiedRIPAbuffer containing the following: 10mMTris, 100
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 nM Na4P2O7, 2 nM
Na3VO4, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10%
glycerol, and 10 l/ml Halt protease/phosphatase inhibitor mixture
(Thermo Scientific). Cell lysates were vortexed for 1 min at RT, incu-
bated on ice for 30min, and then centrifuged for 30min at 4°C to remove
debris. The protein concentration in the supernatant was determined
using a standard BCA protein assay (Thermo Scientific).
The Bio-Rad electroblotting system was used for Western blotting
experiments. To determine the ratio of phosphorylated STAT3 (P-
STAT3) to STAT3, 30 g of protein was diluted 1:3 in loading buffer
(250 mM Tris HCl, 8% SDS, 0.008% bromophenol blue, 20%
-mercaptoethanol, 40%glycerol, pH 6.8), heated to 96°C for 4min, and
then stored on ice for 5 min. Samples and dual-color protein standards
(Bio-Rad) were separated on 10% SDS-polyacrylamide gels using a 3 A
(114 V) current in running buffer (0.19 M Tris, 1.92 M glycine, 0.35 M
SDS in ddH2O) for 1 h. Immobilon PVDF membranes (Millipore) were
primedwith a 15 s wash inmethanol, followed by a 2minwash in ddH2O
and a 5minwash in transfer buffer (4.68Mmethanol in running buffer).
Proteins were then transferred over 1 h onto the membranes using a 3 A
(100 V) current in transfer buffer. After the transfer, membranes were
washed (3 10min) in Tris-buffered saline (TBS)-Tween (TBST; 50mM
Tris, 150 mM NaCl, 0.05% Tween 20), followed by blocking in Odyssey
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blocking buffer (LI-COR) for 1 h at RT on a rotator. Membranes were
then cut and probed with primary antibodies against -actin (1:1000;
Cell Signaling Technology, #4967) and anti-STAT3 (79D7) (1:2000; Cell
Signaling Technology, #4904) overnight at 4°C on a rotator. The follow-
ingmorning, membranes were washed on a rotator at RT (3 10min in
TBST). Next, membranes were incubated with secondary antibody (goat
anti-rabbit IgG-IRDye 800CW (1:20,000; LI-COR, #926-32211) for 1 h
at RT on a rotator. After 3 10 min washes in TBST, blots were imaged
using theOdyssey Infrared Imaging System (LI-COR). Bound antibodies
were then stripped from the membrane using Newblot PVDF stripping
buffer (LI-COR, #928-40032) as per themanufacturer’s instructions, and
the membranes incubated again for 10 min on a rotator in Odyssey
blocking buffer (LI-COR).Membranes were then washed (3 10min in
TBST) and probed for -actin (1:1000; Cell Signaling Technology,
#4967) and P-STAT3 (1:1000; Cell Signaling Technology, #9131) over-
night at 4°C. The nextmorning, blots were washed (3 10min in TBST)
and incubated with secondary antibody (goat anti-rabbit IgG-IRDye
800CW, 1:20,000; LI-COR, #926-32211) for 1 h at RT on a rotator. After
another series of washes in TBST, blots were imaged again using the
Odyssey Infrared Imaging System (LI-COR). The ratio of P-STAT3 to
STAT3 in each lane was calculated after normalization to the -actin
band using the Analyze Gel function in ImageJ.
To confirm C5aR expression by cultured astrocytes, 40 g of protein
was loaded into the Bio-Rad electroblotting system. Rat anti-C5aR anti-
body (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination
with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219),
was used to detect C5aR using similar procedures as detailed above. After
stripping, blots were probed for -actin (1:1000; Cell Signaling Technol-
ogy, #4967) followed by goat anti-rabbit IgG-IRDye 800CW (1:20,000;
LI-COR, #926-32211) to control for loading and confirm appropriate
protein transfer. WT mouse brain homogenate was used as a positive
control. Protein homogenized from C5ar/ mouse brain was also in-
cluded to confirm again the specificity of the antibody that was used to
detect C5aR.
Statistical analysis.GraphPadPrism (GraphPad Software)was used for
all data visualization and statistical analyses. In vivo BMS data were ana-
lyzed using two-way repeated-measures ANOVA with Bonferroni post
hoc tests. Two-sided Student’s t tests were used to directly compare dif-
ferences in lesion size and/or histological data (myelin, GFAP, Ly6b.2,
CD11b, andCD3 staining) at the lesion epicenter. Data from the narrow-
ing beam walk, in vitro cell culture, and Western blot experiments were
analyzed using one-way ANOVAwith Newman–Keuls post hoc tests. For
the comparison of C5a levels in the spinal cord and blood plasma, in vivo
glial cell proliferation/survival, Ly6b.2 and CD3 cell numbers along
the length of the injured cord, and cytokine levels between experimental
groups/conditions, two-way ANOVA with Newman–Keuls post hoc test
was used. Pearson’s correlation test was used to examine the relationship
between astrocyte proliferation and lesion size, and for correlating lesion
volume, myelin or GFAP staining with BMS scores. All data are mean
SEM, with statistical significance determined at p	 0.05.
Results
C5a production and expression of C5aR
C5a levels in homogenized spinal cord and plasma samples were
measured by ELISA to determine the temporal profile of comple-
ment activation after SCI. Baseline C5a levels were low (2.6 
0.25 pg/g protein) in spinal cord samples fromunoperatedmice
(time point 0). C5a levels in samples from naive mice were not
different from samples from sham-operated mice at any time
point after surgery (p  0.05). Following SCI, a rapid and dra-
matic increase in tissue C5a levels was observed, which peaked at
1 d after injury (9.3 1.4 pg/g protein, a 4.5-fold increase over
sham-operated controls). Spinal cord C5a levels were still signif-
icantly higher in SCI mice compared with sham-operated con-
trols at 4 (7.0 1.1 vs 2.2 0.68 pg/g protein) and 7 d (6.1
0.85 vs 1.8 0.63 pg/g protein) after surgery (Fig. 1A). Tissue
C5a levels remained slightly elevated at 35 d after SCI, but this was
not statistically significant compared with sham-operated mice
when using ANOVA. In the plasma, a rapid increase in circulat-
ing C5a levels was observed following SCI, with these being sig-
nificantly elevated above the amount of C5a present in matching
samples from sham-operated mice at 30 min, 2 h, 6 h, 12 h, and
1 d after surgery (Fig. 1B). Although still elevated, C5a levels were
no longer different between sham and SCI mice from 4 d after
injury onwards.
Immunofluorescent staining was used to examine the pattern
and distribution of C5aR expression in the injured spinal cord. At
1 d after SCI, prominentC5aR stainingwas observed on surviving
Iba1 microglia and population of smaller, round/ovoid Iba1
cells that are most likely infiltrating neutrophils (Fig. 1C). At 7 d
after SCI, C5aR stainingwas apparent on cells with amoeboid and
ramified morphology. Staining with Iba1 indicated that many of
these cells were activated microglia and clustered macrophages
(Fig. 1D). C5aR staining also localized to a subset of GFAP
astrocytes in the rim of spared white matter surrounding the
lesion core (Fig. 1E). No C5aR staining was present on injured
spinal cord tissue from C5ar/mice (Fig. 1F), indicating anti-
body specificity. Expression of C5aR by astrocytes was also con-
firmed in vitro through Western blotting (Fig. 1G).
Genetic ablation of C5aR reveals a dual role for C5a signaling
in SCI
BMS locomotor scoring with experimenter blinding was per-
formed on C5ar/ and WT mice for 5 weeks after injury to
determine the contribution of C5aR to SCI outcomes. Before
SCI, all mice displayed normal overground locomotion, achiev-
ing BMS scores of 9. SCI produced near-complete paralysis (BMS
scores 0–1) in all mice at 1 d after SCI. By 7 d after SCI, C5ar/
mice displayed significantly more hindlimbmotor function than
WT mice (p 	 0.05) (Fig. 2A,B). These early improvements
were, however, not sustained and no longer present by 10 d after
SCI. Indeed, by 21 d after SCI,C5ar/mice now showed signs of
impaired functional recovery, and their BMS scores were signif-
icantly below those of WT mice at 28 and 35 d after injury (Fig.
2A,C). Endpoint postmortem analysis of lesion volume and his-
topathology provided additional support of an ultimately poorer
outcome as a result of C5aR ablation. Specifically, a reconstruc-
tion of the lesion site from ex vivoMRI datasets revealed signifi-
cantly larger lesion core volumes in C5ar/ mice compared
with WT mice at 35 d after SCI (Fig. 2D,E; p  0.023). Lesion
core volumes in WT and C5ar/ mice were negatively corre-
lated with the BMS scores of individual animals at the study
endpoint (r2 0.71; p 0.002).
In addition, FluoroMyelin Red staining revealed a reduction
in myelin content in C5ar/ mice (Fig. 2F,G; p  0.012).
GFAP immunoreactivity (Fig. 2F) was also found to be reduced
in C5ar/ mice at 35 d after injury with regards to both the
immunoreactive area (Fig. 2H; p  0.0073) and the intensity of
GFAP staining (Fig. 2I; p  0.017). FluoroMyelin and GFAP
staining at the lesion epicenter of WT and C5ar/ mice was
positively correlated with BMS scores at the study endpoint
(r2  0.73 and r2  0.51, respectively; p 	 0.003). Last, a more
widespread presence of Ly6b.2 cells (Fig. 2J; p  0.0007) and
CD3T cells (Fig. 2K; p 0.0057) was observed along the length
of the spinal cord at the study endpoint.
Acute but not sustained C5aR antagonism improves
SCI outcomes
Because the genetic ablation of C5aR appeared beneficial during
the (sub)acute period of SCI, it was hypothesized that transient
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pharmacological blockade of C5aR during only the first 7 d after
SCI would lead to sustained improvements in SCI recovery. Sim-
ilar to C5ar/ mice, administration of C5aR-A to Macgreen
mice with SCI during the first week of injury resulted in a clear
trend for improved recovery compared with vehicle-treated
Macgreen mice. This improvement was sustained into the more
chronic phase of injury and significantly different from vehicle-
treated controls at 21, 28, and 35 d after injury (p 	 0.05) (Fig.
3A,B). The ledged tapered beam walk test was also used at the
study endpoint as a second, independent measure of the efficacy
of (sub)acute C5aR-A treatment. Sham-operated control mice
had no difficulty mastering this task, making very few mistakes
and crossing the beam relatively fast (Fig. 3C,D). Although SCI
consistently led to impaired performance in this test, C5aR-A-
treated mice made significantly fewer stepping mistakes (p 
0.0024; Fig. 3C) and also traversed the beam faster (p  0.017)
(Fig. 3D) compared with vehicle-treated mice with SCI. Histo-
logical assessment of injured spinal cords at 35 d after SCI con-
firmed attenuated pathology as a result of (sub)acute C5aR-A
treatment, with C5aR-A-treated mice having significantly more
myelin content compared with the vehicle-treated animals (Fig.
3E,F; p 0.0088). TheGFP infiltrate in the lesion core was also
significantly reduced (p  0.0061; Fig. 3E,G). There was, how-
ever, no difference in the GFAP area (p  0.67; Fig. 3H, I) or
staining intensity (p 0.48; Fig. 3H, J) between groups. Collec-
tively, these data indicate that C5aR antagonism, when limited to
a 7 day window during the (sub)acute period of SCI, leads to
improvements in neurological recovery that are sustained into
the chronic phase of injury.
Importantly, continued antagonism of C5aR beyond the first
week of injury in WTmice produced a phenotype similar to that
of C5ar/ mice. Specifically, an early trend toward improved
recovery after C5aR-A treatment was again observed at 7 d after
SCI, but this did not persist into the more chronic phase (Fig.
3K). Thus, the benefits of therapeutically targeting C5aR are an-
nulled if blockade is maintained beyond the first week of spinal
trauma.
C5ar/mice have reduced levels of proinflammatory
cytokines and attenuated macrophage recruitment early after
SCI
To begin exploring why there were consistent signs of improved
recovery during the (sub)acute phase in the absence of C5aR
signaling, we first investigated whether the inflammatory re-
sponse to SCI was altered by C5aR ablation. We theorized that a
dampened production of proinflammatory cytokines acutely af-
ter SCI may have yielded neuroprotection, which in turn under-
pinned the early functional improvements seen inC5ar/mice.
A cytometric bead array (BD Biosciences) was therefore used to
measure the concentration of a panel of cytokines within the
injured spinal cord of WT and C5ar/ mice at 12 h after SCI.
This time point was specifically selected because various key pro-
inflammatory cytokines are elevated or at peak concentrations
here (Pineau and Lacroix, 2007); it also precedes the peak of the
first wave of peripheral immune cell infiltration (i.e., neutro-
phils) (Kigerl et al., 2006; Beck et al., 2010), thereby allowing
some differentiation between leukocyte-derived and glial/neuro-
nally derived cytokines. There was no difference in baseline (i.e.,
sham-surgery) levels of any cytokine between WT and C5ar/
mice (p  0.05). In both genotypes, SCI elicited significant in-
creases in spinal cord levels of MCP-1 (Fig. 4A), TNF (Fig. 4B),
CXCL1 (Fig. 4C), IL-6 (Fig. 4D), IL-1 (Fig. 4E), and IL-10 (Fig.
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Figure1. Productionof C5aandexpressionof C5aR in the injured spinal cord.A, C5aprotein concentration in injuredWTspinal cord is significantly increased comparedwithbothnaive (timepoint
0) and sham levels at 2 h, 6 h, 12 h, 1 d, 4 d, and 7 d after SCI (n 4 or 5 per time point, two-way ANOVAwith Newman–Keuls post hoc tests). *p	 0.05. **p	 0.01. ****p	 0.0001. B, WT C5a
levels are also increased in the plasma in response to SCI, exceeding levels observed in sham-operatedmice at 30min, 2 h, 6 h, 12 h, and 1 d after injury (n 4 or 5 per time point, two-way ANOVA
with Newman–Keuls post hoc tests). *p	 0.05. **p	 0.01. ***p	 0.001. C–E, Representative confocal images showing C5aR expression in the injured spinal cord at 1 and 7 d after injury. C, At
1 d after injury, C5aR appeared present at the lesion epicenter on nucleated Iba1 cells (arrow) aswell as numerous smaller circular/ovoid cells that did not express Iba1 (arrowheads). Scale bar, 6.0
m.D, At 7 d after injury, C5aR is present on cellswith amoeboidmorphology inWTmice,which appear to be clustered Iba1macrophages/microglia (arrow). Scale bar, 10m.E, C5aRexpression
was also observed on more elongated GFAP astrocytes (arrows), alongside C5aRGFAP cells with macrophage-like morphology (arrowhead). Scale bar, 13m. F, Only a very low level of
nonspecific background fluorescence was observed following C5aR staining of lesioned C5ar/ spinal cord tissue. Scale bar, 35 m. G, Representative Western blots demonstrating C5aR
expression by astrocytes in vitro. Left and middle lanes contain WT and C5ar/whole mouse brain homogenates, respectively. Right lane contains protein sample from cultured WT astrocytes.
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4F) over baseline. IL-12p70 and IFN levels were not increased in
response to SCI at this time point in either genotype (data not
shown). Notably, many SCI-induced changes in cytokine levels
were attenuated in the absence of C5aR, with significant re-
ductions observed in CXCL1 (40%, p	 0.05), IL-6 (33%, p	
0.01), and IL-1 (75%, p 	 0.0001) levels within the injured
spinal cord.
We also quantified the number of granulocytes and inflam-
matory monocytes/macrophages at 1 and 7 d after injury (i.e.,
time points that represent the respective peak recruitment/infil-
tration times for these cells). Immunolabeling of Ly6b.2 cells
(which predominantly represent neutrophils acutely after injury)
revealed no statistically significant reduction in the recruitment
of these cells between genotypes at 1 d after SCI (Fig. 4G; p 
0.11). Flow cytometric analysis of the spinal cord at 7 d after SCI
also showed no significant difference in the Ly6G infiltrate be-
tween genotypes (p 0.07; Fig. 4H). There was, however, a clear
reduction in the number of CD45hiLy6CLy6G cells (inflam-
matory monocytes/macrophages) in C5ar/ mice at this time
point (p 0.002) (Fig. 4I). In summary, these findings indicate
that acute disabling of the C5a-C5aR axis significantly reduces
local proinflammatory cytokine production and the recruitment
of inflammatory monocytes/macrophages.
Lack of C5aR in the peripheral immune compartment does
not affect SCI outcomes
Having observed a clear dual and time-dependent role for C5aR
in the response to SCI, we next aimed to better understand the
mechanisms resulting in this phenotype. To this end, BM chime-
ric mice were generated to better appreciate the role of C5aR
expression within the peripheral immune compartment (i.e., cir-
culating leukocytes)with regards to SCI outcomes (Fig. 5A). BMS
locomotor scoring with experimenter blinding revealed that
transplantation of C5ar/ BM into conditioned WT hosts
([C5ar/¡WT] BMchimeras) did not lead to altered recovery
from SCI compared with [WT¡WT] chimerasmice for up to at
least 35 d after SCI (Fig. 5B,C). There were also no statistically
significant differences in lesion histopathology, including the
Figure 2. C5ar/ mice have a dual phenotype after SCI. A, BMS locomotor scoring revealed that C5ar/ mice have significantly improved hindlimb motor function at 7 d after injury
compared with WT mice. This trend reversed with time such that, at 28 and 35 d after SCI, WT mice had regained significantly more motor function than C5ar/mice (two-way ANOVA with
Bonferronipost hoc tests,n8–12).B, PooledBMS scores for individualmice fromvarious experiments at 7 d after injury (Student’s two-sided t test,n18–21).C, Graph showing theBMS scores
for individual mice at 35 d after injury from longitudinal scores plotted in A (Student’s two-sided t test, n 8–12). D, Postmortem T2*-weighted MRI images showing lesion sites in WT and
C5ar/mice. Scale bar (top left image): coronal images, 400m; sagittal images, 1 mm. E, Quantitative analysis revealed significantly larger lesion core volumes in C5ar/mice. Represen-
tative reconstructions of lesion cores for each genotype are shown in gray. F,G, A reduction inmyelin contentwas observed in C5ar/mice at 35 d after SCI (Student’s two-sided t test, n 8 per
group). Scale bar: F (top left image), 200m.H, I, Reductions in the proportional area (H ) and intensity (I ) of GFAP stainingwere also observed in C5ar/mice (Student’s two-sided t tests, n
8 per group). J, K, Amore widespread presence of Ly6b.2 cells (J ) and CD3 T cells (K ) was observed in C5ar/mice at 35 d after injury (two-way ANOVAwith Newman–Keuls post hoc tests,
n 5 per group), as also confirmed by area under the curve analysis (Student’s two-sided t test, n 5 per group). *p	 0.05. **p	 0.01. ***p	 0.001. ****p	 0.0001.
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amount of myelin at the lesion epicenter (Fig. 5D), Ly6b.2 cel-
lular infiltrate (Fig. 5E), CD11b immunoreactivity (Fig. 5F),
andCD3T-cell numbers (Fig. 5G). Together, these data suggest
that both the early injurious role of C5aR and its more delayed
neuroprotective/reparative actions in the postacute phase are
mostly mediated through resident CNS cells and not circulating
immune cells.
C5aR regulates astrocyte proliferation and glial scar
formation in vivo
Our next aim was to understand why genetic ablation or contin-
ued pharmacological blockade of C5aR adversely affected recov-
ery in the more chronic period of SCI. Based on one of our initial
observations that C5ar/ mice had reduced myelin content at
35 d after SCI (Fig. 2F,G), we first explored whether C5aR sig-
naling may be required for oligodendrocyte precursor cell prolif-
eration (and/or survival) in response to SCI. To test this, BrdU
was administered daily for the first 7 d after SCI to WT mice that
were treated for 21 d with either C5aR-A or vehicle, as well as to a
cohortof vehicle-treatedC5ar/mice.Theexperimental endpoint
of 21 d after SCI was chosen based on a previous study showing that
deficiency in C5 (i.e., the parental protein fromwhich C5a is gener-
ated) leads to impaired remyelination in experimental autoimmune
encephalitis at this stage (Weerth et al., 2003).
Quantification of the total (CC1) and newly generated
(CC1BrdU) oligodendrocytes in spared white matter at and
Figure 3. Acute, but not sustained, antagonism of C5aR improves SCI outcomes inMacgreenmice.A, BMS locomotor scores ofmice treatedwith a C5aR antagonist (C5aR-A) for 7 d after SCI have
significantly higher BMS scores than vehicle (Veh)-treated mice at 21, 28, and 35 d after injury. *p	 0.05 (two-way ANOVA with Bonferroni post hoc tests, n 8–10). B, A scatter plot depicting
the BMS scores of individualmice at 35 d after SCI. *p 0.029 (Student’s two-tailed t test, n 8–10). C,D, Data from the ledged tapered beamwalk task also indicated that C5aR blockade during
the acute period improved long-term recovery,with C5aR-A-treatedmicemaking significantly fewer steppingmistakes (C), and also traversing the beam faster (D) than vehicle-treated SCI controls.
*p	 0.05; **p	 0.01; ***p	 0.001; ****p	 0.0001 (one-way ANOVAwith Newman–Keuls post hoc tests, n 6–10). E, F, (Sub)acute C5aR-A treatment resulted in significantlymoremyelin
being present at the lesion epicenter at 35 d after SCI comparedwith vehicle-treatedmice. **p 0.0088 (Student’s t test, n 5 per group). Scale bar: E (top left), 200m. E,G, The GFP infiltrate
in the lesion coreofMacgreenmicewasalso significantly reduced following theC5aR-A treatment regimen. **p0.0061 (Student’s two-sided t test,n5pergroup).H–J, GFAP immunoreactivity
at 35 d after SCI was not significantly different between treatment groups based on analysis of both proportional area (I ) and staining intensity (J ). Scale bar: H (top left), 200m. K, Improved
recovery from SCI was not sustained with continued C5aR-A administration. *p	 0.05, C5ar/ vehicle versus WT vehicle (two-way ANOVA with Bonferroni post hoc tests, n 4 or 5).
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around the lesion epicenter at 21 d after SCI revealed no signifi-
cant differences between any of the experimental groups (p 
0.93). Specifically, a total of 27  7 newborn oligodendrocytes
were observed at the lesion epicenter in vehicle-treatedWTmice
comparedwith 29 4 cells inC5aR-A-treatedWTmice and 26
3 cells forC5ar/mice. Total CC1 cell numbers were also not
different between the experimental groups (p  0.94), with
356  46 cells counted in vehicle-treated controls compared
with 351 65 cells for C5aR-A-treatedWTmice and 328 57
cells for C5ar/mice. We also observed no differences in the
number of apoptotic (Cleaved Caspase-3 CC1) oligoden-
drocytes between the experimental groups at the lesion epi-
center (p  0.87). Specifically, a total of 10  3 cells was
counted here in vehicle-treated WT mice, compared with 9
2 cells in C5aR-A-treated WT mice and 11  2 cells in
C5ar/ mice. Similar results for each of the above quantita-
tive analyses were obtained between experimental groups for
distances up to at least 600 m in both
rostral and caudal directions (data not
shown).
Given that neither genetic nor phar-
macological disabling of the C5a-C5aR
axis appeared to affect oligodendrocyte
generation and survival, we next inves-
tigated whether astrocyte proliferation
was impaired under C5aR-deficient
conditions. Quantification of
BrdUGFAP cells revealed that there
was a significant reduction in the number
of newly generated astrocytes present at
the lesion margins in the absence of C5aR
signaling at 21 d after SCI (Fig. 6A; p 	
0.05). These findings are in agreement
with the observation that C5ar/ mice
had less GFAP immunoreactivity at 35 d
after SCI (Fig. 2F,H,I), and indicate that
impaired formation of the glial scar may
have led to a greater spread of secondary
injury due to a failure to effectively seal off
the lesion site (Faulkner et al., 2004; Herr-
mann et al., 2008). Consistent with that, the
total number of BrdUGFAP astrocytes
across the analyzed segment of the le-
sioned spinal cord was strongly and nega-
tively correlated with the lesion volume
(Fig. 6B; p	 0.0001).
C5a promotes astrocyte proliferation
and STAT3 phosphorylation in vitro
Given the observation that interference
with C5aR signaling reduced astrocyte
proliferation in vivo, we next directly
tested the premise that C5a promotes the
proliferation of these cells in vitro. Expo-
sure of cultured astrocytes to C5a indeed
elicited a dose-dependent proliferative re-
sponse, with significantly more astrocytes
being present in the cultures following
stimulation with C5a concentrations of
10, 50 100, and 200 nM compared with
baseline (Fig. 6C). Having already estab-
lished that cultured astrocytes express
C5aR (Fig. 1G), we next examined
whether the proliferative effect of C5a was mediated via activa-
tion of this particular receptor. Exposure of C5ar/ astrocytes
to C5a failed to induce a proliferative response (Fig. 6D), thereby
confirming that this effect requires the presence of C5aR.
Based on previous demonstrations that activation of the
STAT3 pathway plays a critical role in astrocyte proliferation and
the neuroprotective properties of the glial scar (Okada et al.,
2006; Herrmann et al., 2008; Wanner et al., 2013), we next inves-
tigated whether STAT3 phosphorylation in astrocytes occurs
downstream of C5aR following C5a stimulation. The amount of
phosphorylated STAT3 (P-STAT3) was found to bemarkedly (2.5-
fold) increased in response to C5a stimulation (50 nM), an effect
that could be blocked if the STAT3 inhibitor BP-1-102 was added
just before C5a exposure (Fig. 6E). No increase in STAT3 phos-
phorylation was observed in C5ar/ astrocytes following expo-
sure to C5a (Fig. 6F). In the final experiment, we tested whether
Figure 4. Inflammation in the (sub)acute period of SCI is reduced with C5aR elimination. A–F, Levels of MCP-1 (A), TNF (B),
CXCL1 (C), IL-6 (D), IL-1 (E), and IL-10 (F )wereall significantly increasedat12hafter SCI comparedwith sham-operated controls,
regardless of genotype. C5aRdeficiency did, however, result in significant reductions in CXCL1, IL-6, and IL-1 in the injured spinal
cord compared with WT mice. *p	 0.05; **p	 0.01; ***p	 0.001; ****p	 0.0001 (two-way ANOVA with Newman–Keuls
post hoc tests, n 4 or 5).G,H, No significant differences in the Ly6b.2 inflammatory cell infiltrate were observed betweenWT
and C5ar/mice at 1 d (G) and 7 d (H ) after SCI. Scale bar: G (bottom image), 40m. I, A significant reduction in the number
of inflammatory monocytes/macrophages was observed in injured C5ar/ spinal cord at 7 d after SCI. **p	 0.01 (Student’s
two-sided t test). n 5 per group.
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activation of the STAT3 pathway was driving astrocyte prolifer-
ation in response to C5a. Treatment with BP-1-102 indeed an-
nulled the proliferative effect of C5a on astrocytes (Fig. 6G).
Collectively, these findings indicate that C5a-induced phosphor-
ylation of STAT3 occurs downstream of C5aR, which in turn
drives astrocyte proliferation.
Discussion
Complement activation in CNS injury is predominantly consid-
ered deleterious to recovery. Specifically, complement proteins
are thought to contribute to secondary injury through opsoniza-
tion and membrane attack complex formation (for review, see
Brennan et al., 2012). Other complement activation products
appear to have more complex or even biphasic roles (Beck et al.,
2010).We report that eliminating C5aR signaling attenuates pro-
inflammatory cytokine expression at the lesion site acutely after
injury. This was followed by reduced macrophage recruitment
and improved recovery of hindlimb function at 7 d after SCI.
Importantly, and consistent with Beck et al. (2010), lack of C5aR
signaling in the postacute period was detrimental to recovery.
Experiments in BM chimeric mice suggested that these dual and
opposing roles of C5aR are predominantly mediated via CNS
cells and not infiltrating immune cells. Additional in vivo and in
vitro studies demonstrated that C5aR signaling regulates astro-
cyte proliferation, at least partly by STAT3 phosphorylation. We
therefore postulate that whereas acute/subacute blockade of
C5aR improves recovery, prolonged interference with C5aR sig-
naling leads to impaired scar formation and reduced ability to
confine pathology, as evidenced by poorer neurological recovery,
larger lesion volumes, andmore widespread presence of immune
cells along the spinal axis.
Time course of complement activation in SCI
Previous studies clearly demonstrated the occurrence of comple-
ment system activation following SCI, with abnormal expression
and/or deposition of C1q, factor B, C3, C4, C7, and membrane
attack complex on neurons, glia, and infiltrating immune cells
(Anderson et al., 2004; Qiao et al., 2006; Nguyen et al., 2008;
Ankeny et al., 2009). The present data show that complement
activation peaks locally at 12–24 h after SCI based on C5a levels.
Extrinsic pathway activity likely plays a major role in C5a gener-
ation during this early phase due tomicrohemorrhaging (Huber-
Lang et al., 2006). C5a levels remained significantly elevated up to
7 d after SCI but decreased thereafter to concentrations that were
only slightly elevated from baseline. SCI also elicited a sharp rise
in plasma C5a levels, which were significantly elevated over
sham-operated controls up to 1 d after injury. Thus, robust in-
creases inC5a levels occur in the blood and spinal cord during the
first week of injury.
Figure 5. C5aR deficiency in the peripheral immune compartment does not alter the outcome from SCI.A, Flow cytometry data showing chimerization efficacy. [C5ar/¡WT] BM chimeras
(i.e., WTmice that received a C5ar/ bonemarrow transplant) only express background levels of C5aR on circulating granulocytes, equivalent to the amount of nonspecific staining observed on
C5ar/ cells. ***p	0.001 (one-wayANOVAwithNewman–Keulspost hoc).n3–7.B, BMS locomotor scoring revealedno significantdifferences in functional recoveryas a result of select C5aR
deficiency in the peripheral immune compartment compared with [WT¡WT] controls (two-way ANOVA with Bonferroni post hoc tests; n 6 or 7). C, Scatter plot showing main BMS scores for
individualmice at 35dafter SCI.D, Nodifferencewas observedbetween the experimental groups in the amount ofmyelinwithin the ventrolateralwhitematter at 35dafter SCI (Student’s two-sided
t test, p 0.05; n 6 or 7). Scale bar:D (top), 200m. E–G, Quantification of the inflammatory infiltrate also showed no differences between the experimental groups in the number of Ly6b.2
cells (E), the proportional area of CD11b immunoreactivity (F ), and the number of CD3 lymphocytes (G) present at the lesion epicenter (Student’s two-sided t tests, p 0.05; n 6 or 7).
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C5aR inhibition in the acute/(sub)acute phase improves
SCI recovery
Characterization of the cellular infiltrate showed that recruit-
ment of CD45hiLy6CLy6G granulocytes was not affected by
C5aR deficiency at both 1 and 7 d after SCI. There was, however,
a clear and significant reduction in the CD45hiLy6CLy6G in-
filtrate at 7 d after SCI in C5ar/ mice, suggesting reduced
recruitment of inflammatory monocytes/macrophages (Blom-
ster et al., 2013a). Overall, these findings are in agreement with
previous observations that C5aR antagonism in an equivalent rat
model does not dramatically alter granulocyte presence but
markedly reduces the number of ED1 microglia/macrophages
at 7 d after injury (Beck et al., 2010). Collectively, these data
suggest that blockingC5aR signaling attenuates activation and/or
recruitment of select inflammatory cell populations, which coin-
cides with improved recovery early on.
AsC5aR is expressed in theCNS andperipheral immune com-
partment (Woodruff et al., 2010), BM chimera experiments were
performed to determine the impact of C5aR deficiency exclu-
sively on circulating leukocytes in relation to SCI outcomes. The
outcome of these experiments suggested that the dual and oppos-
ing roles of C5aR in SCI are predominantly mediated via CNS-
resident cells. Consistent with this, injury-induced expression of
IL-6, IL-1, and CXCL1 within the spinal cord was significantly
abrogated in absence of C5aR signaling at 12 h after SCI, a time
point that coincides with high complement activation but pre-
cedes the first major wave of leukocyte infiltration (Kigerl et al.,
2006; Beck et al., 2010).
IL-1 has previously been shown to promote injurious local
inflammation, which correlates with impaired functional recov-
ery (de Rivero Vaccari et al., 2012; Boato et al., 2013). Similarly,
IL-6 polarizes macrophage toward a proinflammatory M1 phe-
notype, and treatment with anti-IL-6 antibody leads to a pre-
dominance of tissue-reparative M2 macrophages and improved
recovery (Mukaino et al., 2010; Guerrero et al., 2012). Although
we did not identify the precise cell population(s) responsible for
proinflammatory cytokine production, astrocytes and microglia
are likely candidates as they express C5aR (Fig. 1C) and rapidly
respond to trauma (Pineau and Lacroix, 2007; Donnelly and
Popovich, 2008; Pineau et al., 2010). We therefore postulate that
the benefits of C5aR blockade during the acute/subacute phase of
Figure 6. Signaling through the C5a-C5aR axis promotes astrocyte proliferation in vivo and in vitro. A, Quantification of BrdUGFAP astrocytes at the lesion site of WT SCI mice that were
chronically administered C5aR-A (orange) or vehicle (Veh, blue) solution, and vehicle-treated C5ar/mice (red). Note the significantly reduced presence of newly generated astrocytes along the
rostral and caudal margins of the lesion in the absence of C5aR signaling (two-way ANOVA with Newman–Keuls post hoc tests; n 4 or 5 per group). *p	 0.05. **p	 0.01. B, A significant,
negative correlation was observed between the total number of BrdUGFAP cells and lesion volumes (Pearson’s correlation, p	 0.0001). C, C5a stimulates the proliferation ofWT astrocytes in
vitro in adose-dependentmanner at concentrations10nM (one-wayANOVAwithNewman–Keulspost hoc tests). *p	0.05. ***p	0.001.Graph is representativeof three experimental repeats.
D,C5ar/astrocytesdidnotproliferate in response tohigh-doseC5a (50nM; Student’s two-sided t test,p0.05).E, Exposureof culturedastrocytes toC5a (50nM) resulted ina significant increase
in the ratio of P-STAT3 to STAT3. Addition of the STAT3 Inhibitor BP-1-102 (10M) just before C5a stimulation blocked this increase in STAT3phosphorylation (one-wayANOVAwithNewman–Keuls
post hoc tests). **p	 0.01. F, Stimulation of C5ar/ astrocyteswith 50 nM of C5a did not lead to a significant change in STAT3 phosphorylation (Student’s two-sided t test, p 0.05).G, Addition
of BP-1-102 (5M) blocked C5a-induced astrocyte proliferation in vitro (one-way ANOVAwith Newman–Keuls post hoc tests). **p	 0.01. ***p	 0.001. Dotted line indicates the initial number
of cells plated. D–F, Data are mean SEM, with n 6 biological replicates. ns, Not significant.
Brennan et al. • C5aR Controls Neuroinflammation in SCI J. Neurosci., April 22, 2015 • 35(16):6517–6531 • 6527
SCI are primarily mediated through reduced proinflammatory
cytokine production and associated neuroprotection (Farkas et
al., 1998; Humayun et al., 2009; Pavlovski et al., 2012), with re-
duced recruitment of inflammatory Ly6C monocytes/macro-
phages at 7 d after SCI as a direct reflection of attenuated
secondary injury. Targeting the C5a-C5aR pathway during the
first hours to days after SCI is thus a credible therapeutic avenue
to promote SCI recovery (Fig. 7).
C5aR activation regulates astrocyte proliferation and
glial scarring
Although our findings clearly demonstrate that C5aR activation
is deleterious to recovery in the acute/subacute period of SCI, lack
of C5aR signaling in the chronic phase ultimately led to exacer-
bated injury outcomes. Specifically, C5ar/ mice exhibited
lower BMS scores, larger lesion volumes, less white matter my-
elin, and reduced glial scarring at 35 d after injury. Improvements
obtained through pharmacological blockade of C5aR were also
lost if treatment was extended beyond the acute phase. Although
a recent study by Li et al. (2014) did not report such a dual role for
C5aR, our findings are consistent with earlier observations by
Beck et al. (2010) who independently showed that chronic
C5aR-A treatment similarly impairs recovery in rats. Unfortu-
nately, Li et al. (2014) did not report lesion volumes or axonal/
myelin sparing as an independent accompaniment to functional
testing,making a direct comparison between our studies difficult;
additional differences in the lesion model of choice (computer-
controlled impact vs manual compression with forceps) and
mouse strains used (C57BL/6J vs BALB/c) (Kigerl et al., 2006) are
likely contributors to this disparity. Regardless, the mecha-
nism(s) contributing to the reparative/neuroprotective role of
C5aR in contusive SCI had remained unclear. Although previous
studies suggested a possible role for C5a in reparative remyelina-
tion following cuprizone treatment (Ingersoll et al., 2010), oligo-
dendrocyte survival and/or proliferation of oligodendrocyte
precursor cells appeared unaffected by disabling C5aR signaling
in the context of SCI. As we observed a reduction in GFAP
immunoreactivity in C5ar/ mice at the study endpoint, we
investigated whether C5aR signaling had any effect on astrocyte
proliferation. Our in vivo data revealed that both genetic ablation
and pharmacological blockade of C5aR inhibit astrocyte prolif-
eration. This finding was supported by additional in vitro data
showing that activation of C5aR by C5a induces astrocyte prolif-
eration in a dose-dependent manner.
With previous research indicating a key role for STAT3 in
protective glial scar formation (Okada et al., 2006; Herrmann et
al., 2008; Wanner et al., 2013), we evaluated whether C5aR sig-
naling in astrocytes promotes STAT3 pathway activation. Expo-
sure of cultured astrocytes to C5a indeed leads to STAT3
phosphorylation via C5aR, an event that is critical for initiating
downstream transcriptional events and cell proliferation. In-
triguingly, Okada et al. (2004) demonstrated that IL-6 also pro-
motes astrocyte proliferation via STAT3, which could be
inhibited with anti-IL-6R antibody treatment (Okada et al.,
2004). As we observed reduced IL-6 levels in C5ar/mice, it is
likely that this may have further impaired astrocyte proliferation
in vivo. Activation of the C5a-C5aR axis may thus stimulate as-
trocyte proliferation directly as well as indirectly via IL-6 release
from astrocytes and/or microglia.
Figure 7. Diagram showing the proposed dual and time-dependent role of C5aR in SCI. In the (sub)acute period (0–7 d after SCI), activated astrocytes andmicroglia proliferate and/or migrate
to the site of injury. Activation of these cells occurs in part through increased C5a levels as a result of complement activation, which in turn augments their production and release of inflammatory
cytokines at the lesion site. Release of CXCL1 is a key signal for neutrophil recruitment to the site of SCI. IL-1 and IL-6 aid in the recruitment of bloodmonocytes andmacrophages, which promote
secondary injury if adopting an M1 phenotype. In the postacute to chronic period of SCI (7 d after SCI onwards), C5aR signaling is critically required for STAT3-mediated astrocyte proliferation and
glial scar formation, which seals the injury site and prevents the spread of secondary injury. Through its regulation of IL-6 levels, C5aRmay also be involved IL-6R-dependent astrocyte proliferation.
1(Andersonet al., 2004, 2005;Nguyenet al., 2008); 2(Lacyet al., 1995;Griffin et al., 2007;Ager et al., 2010); 3(Gasqueet al., 1995; Lacyet al., 1995;Woodruff et al., 2008); 4(Acarin et al., 2000; Pineau
and Lacroix, 2007; Pineau et al., 2010); 5(Klusman and Schwab, 1997; Romano et al., 1997; Dinarello, 2009); 6(Baggiolini and Clark-Lewis, 1992; Harada et al., 1994; Taub et al., 1996); 7(Gensel et
al., 2009; Kigerl et al., 2009; Blomster et al., 2013a); 8(Gensel et al., 2009; Shechter et al., 2009, 2013); 9(Okada et al., 2006); and 10(Bush et al., 1999; Faulkner et al., 2004; Okada et al., 2006;
Herrmann et al., 2008; Wanner et al., 2013).
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Importantly, pleiotropic roles for astrocytes and the glial scar
have been ascribed (i.e., inhibitory from a regeneration perspec-
tive but neuroprotective with regards to secondary injury) (Bush
et al., 1999; Faulkner et al., 2004; Silver and Miller, 2004; Rolls et
al., 2009; Pineau et al., 2010; Cregg et al., 2014; Pekny et al., 2014).
On the latter, demarcation of the lesion is achieved partly
through astrocyte hyperplasia, which increases cell density up to
fourfold in spinal whitematter (Ertu¨rk et al., 2012). By separating
the injury core from neighboring intact neural tissue, astrocytes
limit the spread of immune cells along the spinal axis, as previ-
ously reported (Okada et al., 2006), and observed here for the
Ly6b.2 and CD3 infiltrate. We therefore postulate that the
reparative/neuroprotective functions attributed to C5aR signal-
ing in the postacute phase of SCI (Beck et al., 2010) include its
role in glial scar formation. Whether exogenous stimulation of
astrocyte proliferation via C5aR agonism during the postacute
phase could indeed benefit recovery remains an outstanding
question. It is also worth mentioning that our findings do not
necessarily exclude a role for the alternate C5a receptor, C5L2, in
SCI. They do, however, show that, at least for the induction of
proinflammatory cytokine expression and astrocyte prolifera-
tion, expression of C5aR is required.
In conclusion, the present findings confirmC5aR as a promising
therapeutic target in SCI, demonstrating that timely pharmacologi-
cal inhibitionof this receptor can reduce immune-mediated second-
arydamage and improve recovery.The identified key role forC5aR
signaling in astrocyte proliferation and glial scarring during the
chronic phase of SCI also highlights the importance, however, of
fully understanding the dual and time-dependent functions that
inflammatory mediators like C5a may have, such that adverse
outcomes can be prevented by restricting treatments to critical
windows.
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